Enlyton - Press Room

	PRESS ROOM
		Press Releases
		Events
		Publications

Press Room

Events

Enlyton Secures Rights to Portfolio of Monoclonal Antibodies for Use in Cancer Imaging and Detection

Columbus, Ohio (April 2008) – Enlyton, Ltd. has secured exclusive worldwide rights from NIH to a portfolio of monoclonal antibodies for multiple fields of use in cancer imaging and detection modalities. These antibodies have exhibited high specificity for adenocarcinoma cancers, making them good candidates for use as molecular targets in drug delivery. Details to follow..

Enlyton and The Ohio State University Research Foundation (OSURF) Form Cooperation on Sponsored Research

Columbus Ohio (March 2007) – Enlyton, Ltd. and The Ohio State University Research Foundation (OSURF) entered into a License and Option Agreement that provides Enlyton with exclusive commercialization rights to patented technology involving the surgical detection and removal of occult tumor tissue. The Agreement also affords Enlyton the opportunity to secure option rights to inventions resulting from separate Enlyton-initiated Sponsored Research Agreements involving developments by Ohio State employees. Terms and conditions for each such opportunity are incorporated in this Agreement.

Enlyton is integrating proprietary molecular targets into cancer-specific imaging agents and techniques for use in tumor localization and visualization as the means to improve the treatment of cancer. Enlyton will initially validate its first proprietary cancer-specific molecular target (ATA-1) for use in improving the cancer detection capability of PET/CT.